— Akebia Therapeutics (NASDAQ: AKBA) reported fourth quarter 2019 loss of $0.79 per share vs. expected loss of $0.47 per share.
— Revenue rose 16% to $69.6 million vs. $93.15 million expected.
— Net product revenue more than quadrupled to $28.9 million from $6.8 million in the fourth quarter of 2018.
— R&D expenses were $80.4 million for the fourth quarter of 2019 compared to $87.1 million for the fourth quarter of 2018.
— Akebia continues to expect to share the data from global Phase 3 studies of its anemia treatment drug Vadadustat in the second quarter of 2020.
— AKBA stock dipped more than 5% in the pre-market trading session.
Walt Disney (DIS): After a tough FY20, the pandemic is likely to take a toll on operations next year too
The Walt Disney Company (NYSE: DIS) had a tough time in fiscal year 2020 with the COVID-19 pandemic bringing its operations to a standstill like never before. The company incurred
The recent optimism about economic recovery waned slightly this week after jobless claims increased more-than-expected to about 778,000 amid concerns over a resurgence in coronavirus cases. With the healthcare system
Yunji Inc. (NASDAQ: YJ) Q3 2020 earnings call dated Nov. 26, 2020 Corporate Participants: Kaye Liu -- Investor Relations Director Shanglue Xiao -- Chairman of the Board of Directors and Chief Executive Officer Chen